NGM BIOPHARMACEUTICALS INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2018 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Ngm Biopharmaceuticals Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q4 2023.
  • Ngm Biopharmaceuticals Inc Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2023 was -$27.7M, a 24.1% increase year-over-year.
  • Ngm Biopharmaceuticals Inc Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2023 was -$142M, a 12.5% increase year-over-year.
  • Ngm Biopharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2023 was -$142M, a 12.5% increase from 2022.
  • Ngm Biopharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2022 was -$163M, a 35.2% decline from 2021.
  • Ngm Biopharmaceuticals Inc annual Net Income (Loss) Attributable to Parent for 2021 was -$120M, a 17.4% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 -$142M -$27.7M +$8.77M +24.1% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-11
Q3 2023 -$151M -$28.8M +$18.5M +39.1% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-02
Q2 2023 -$170M -$38.3M +$8.26M +17.8% Apr 1, 2023 Jun 30, 2023 10-Q 2023-11-02
Q1 2023 -$178M -$47.6M -$15.2M -46.8% Jan 1, 2023 Mar 31, 2023 10-Q 2023-11-02
Q4 2022 -$163M -$36.4M -$9.2M -33.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 -$153M -$47.3M -$18.4M -63.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 -$135M -$46.5M -$9.83M -26.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-02
Q1 2022 -$125M -$32.5M -$4.91M -17.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-02
Q4 2021 -$120M -$27.2M +$757K +2.7% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-11
Q3 2021 -$121M -$28.9M +$900K +3.02% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$122M -$36.7M -$11.1M -43.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-03
Q1 2021 -$111M -$27.5M -$8.43M -44.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-03
Q4 2020 -$102M -$28M -$12.1M -75.6% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$90.4M -$29.8M -$18.8M -173% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$71.6M -$25.6M -$17.9M -234% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-04
Q1 2020 -$53.6M -$19.1M -$10.8M -131% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-04
Q4 2019 -$42.8M -$15.9M -$30.1M -213% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-17
Q3 2019 -$12.7M -$10.9M -$3.4M -45.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$9.29M -$7.67M -$4.47M -140% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$4.82M -$8.27M -$4.33M -110% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
Q4 2018 -$493K $14.2M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-17
Q3 2018 -$7.52M Jul 1, 2018 Sep 30, 2018 10-K 2020-03-17
Q2 2018 -$3.2M Apr 1, 2018 Jun 30, 2018 10-K 2020-03-17
Q1 2018 -$3.94M Jan 1, 2018 Mar 31, 2018 10-K 2020-03-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.